140 related articles for article (PubMed ID: 37917641)
61. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
62. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y
J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651
[TBL] [Abstract][Full Text] [Related]
63. Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
Zhou Y; Shen JK; Yu Z; Hornicek FJ; Kan Q; Duan Z
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1573-1582. PubMed ID: 29452249
[TBL] [Abstract][Full Text] [Related]
64. Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells.
Lin SY; Lai WW; Chou CC; Kuo HM; Li TM; Chung JG; Yang JH
Melanoma Res; 2006 Dec; 16(6):509-19. PubMed ID: 17119452
[TBL] [Abstract][Full Text] [Related]
65. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Mavrakis KJ; McDonald ER; Schlabach MR; Billy E; Hoffman GR; deWeck A; Ruddy DA; Venkatesan K; Yu J; McAllister G; Stump M; deBeaumont R; Ho S; Yue Y; Liu Y; Yan-Neale Y; Yang G; Lin F; Yin H; Gao H; Kipp DR; Zhao S; McNamara JT; Sprague ER; Zheng B; Lin Y; Cho YS; Gu J; Crawford K; Ciccone D; Vitari AC; Lai A; Capka V; Hurov K; Porter JA; Tallarico J; Mickanin C; Lees E; Pagliarini R; Keen N; Schmelzle T; Hofmann F; Stegmeier F; Sellers WR
Science; 2016 Mar; 351(6278):1208-13. PubMed ID: 26912361
[TBL] [Abstract][Full Text] [Related]
66. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
Wright GM; Gimbrone NT; Sarcar B; Percy TR; Gordián ER; Kinose F; Sumi NJ; Rix U; Cress WD
PLoS One; 2021; 16(6):e0252927. PubMed ID: 34138895
[TBL] [Abstract][Full Text] [Related]
67. MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.
Bustos MA; Ono S; Marzese DM; Oyama T; Iida Y; Cheung G; Nelson N; Hsu SC; Yu Q; Hoon DSB
J Invest Dermatol; 2017 Sep; 137(9):1955-1964. PubMed ID: 28526299
[TBL] [Abstract][Full Text] [Related]
68. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
69. Genome wide comparative analysis of the effects of PRMT5 and PRMT4/CARM1 arginine methyltransferases on the Arabidopsis thaliana transcriptome.
Hernando CE; Sanchez SE; Mancini E; Yanovsky MJ
BMC Genomics; 2015 Mar; 16(1):192. PubMed ID: 25880665
[TBL] [Abstract][Full Text] [Related]
70. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA
Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002
[TBL] [Abstract][Full Text] [Related]
71. Fluorescent peptide biosensor for monitoring CDK4/cyclin D kinase activity in melanoma cell extracts, mouse xenografts and skin biopsies.
Prével C; Pellerano M; González-Vera JA; Henri P; Meunier L; Vollaire J; Josserand V; Morris MC
Biosens Bioelectron; 2016 Nov; 85():371-380. PubMed ID: 27203461
[TBL] [Abstract][Full Text] [Related]
72. PRMT5 regulates IRES-dependent translation via methylation of hnRNP A1.
Gao G; Dhar S; Bedford MT
Nucleic Acids Res; 2017 May; 45(8):4359-4369. PubMed ID: 28115626
[TBL] [Abstract][Full Text] [Related]
73. Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
Res Sq; 2023 Jul; ():. PubMed ID: 37502925
[TBL] [Abstract][Full Text] [Related]
74. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
[No Abstract] [Full Text] [Related]
75. Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies.
Zheng J; Li B; Wu Y; Wu X; Wang Y
J Med Chem; 2023 Jul; 66(13):8407-8427. PubMed ID: 37366223
[TBL] [Abstract][Full Text] [Related]
76. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
[TBL] [Abstract][Full Text] [Related]
77. PRMT5 activates AKT via methylation to promote tumor metastasis.
Huang L; Zhang XO; Rozen EJ; Sun X; Sallis B; Verdejo-Torres O; Wigglesworth K; Moon D; Huang T; Cavaretta JP; Wang G; Zhang L; Shohet JM; Lee MM; Wu Q
Nat Commun; 2022 Jul; 13(1):3955. PubMed ID: 35803962
[TBL] [Abstract][Full Text] [Related]
78. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy.
Shimizu D; Kanda M; Sugimoto H; Shibata M; Tanaka H; Takami H; Iwata N; Hayashi M; Tanaka C; Kobayashi D; Yamada S; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
Int J Oncol; 2017 Feb; 50(2):381-386. PubMed ID: 28101581
[TBL] [Abstract][Full Text] [Related]
79. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition.
Guiley KZ; Stevenson JW; Lou K; Barkovich KJ; Kumarasamy V; Wijeratne TU; Bunch KL; Tripathi S; Knudsen ES; Witkiewicz AK; Shokat KM; Rubin SM
Science; 2019 Dec; 366(6471):. PubMed ID: 31831640
[TBL] [Abstract][Full Text] [Related]
80. PRMT5 Promotes Human Lung Cancer Cell Apoptosis via Akt/Gsk3β Signaling Induced by Resveratrol.
Li Y; Yang Y; Liu X; Long Y; Zheng Y
Cell Transplant; 2019 Dec; 28(12):1664-1673. PubMed ID: 31665911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
